{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:12:20Z","timestamp":1792645940283,"version":"4.5.0"},"reference-count":63,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec id=\"ab-yoi250081-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Psychedelic-assisted therapy (PAT) trials have high levels of functional unblinding, which biases results when comparing PAT with blinded interventions. Because PAT is effectively always open label, treatment results should be compared with those of open-label traditional antidepressants (TADs), so potential benefits associated with patients knowing their treatment is equal between the interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-yoi250081-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the comparative effectiveness of PAT vs open-label traditional antidepressants (TADs; such as selective serotonin and norepinephrine reuptake inhibitors) for the treatment of major depression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-yoi250081-6\">\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>PubMed was systematically searched in March 2024 for trials of PAT and open-label TADs for the treatment of major depression without comorbidity in adults without psychosis in the outpatient setting. Extraction was supplemented with data from a review and meta-analysis of antidepressant drugs to assess the open-label vs blinded TAD difference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-yoi250081-7\">\n                    <jats:title>Data Extraction and Synthesis<\/jats:title>\n                    <jats:p>Depression scores were extracted by 2 independent reviewers; estimates were pooled with both bayesian and frequentist mixed-effects models. Reporting follows the PRISMA guideline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-yoi250081-8\">\n                    <jats:title>Main Outcomes and Measure<\/jats:title>\n                    <jats:p>Following predefined hypotheses, the mean within-arm effect from baseline to primary end point (ie, patient improvement between PAT and open-label TAD trials on the 17-item Hamilton Depression Rating Scale) was compared. To assess the potential role of blinding, the within-arm effect of blinded vs open-label trials in both PAT and TADs was also compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-yoi250081-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the initially retrieved PubMed 619 records, 24 met inclusion criteria. Contrary to the first of 3 hypotheses, PAT (8 trials; 249 patients) was no more effective than open-label TAD treatment (16 open-label TAD trials; 7921 patients), with an estimated difference of 0.3 favoring open-label TADs (95% CI, \u22121.39 to 1.98;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.73). Open-label TADs were associated with better outcomes than blinded treatment (144 blinded TAD trials; 31\u202f792 patients), with an estimated difference of 1.3 (95% CI, 0.07-2.51;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.04;), but the same difference was not observed for PAT (0.67; 95% CI, \u22123.08 to 1.73;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.58).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-yoi250081-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In trials of depression, PAT was not more effective than open-label TADs. Blinding made a difference for TADs, but not for PAT, confirming that PAT trials are effectively always open label. These results argue against highly optimistic narratives surrounding PAT and highlight the importance of blinding integrity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2025.4809","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:30:50Z","timestamp":1773847850000},"page":"461","source":"Crossref","is-referenced-by-count":23,"title":["Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding Conditions"],"prefix":"10.1001","volume":"83","author":[{"given":"Zachary J.","family":"Williams","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles"},{"name":"Frist Center for Autism and Innovation, Vanderbilt University School of Engineering, Nashville, Tennessee"},{"name":"A.J. Drexel Autism Institute, Drexel University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Barnett","sequence":"additional","affiliation":[{"name":"Centre for Psychedelic Research, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Szigeti","sequence":"additional","affiliation":[{"name":"Centre for Psychedelic Research, Imperial College London, London, United Kingdom"},{"name":"Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"yoi250081r1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1176\/appi.focus.16407","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.","volume":"16","author":"Cipriani","year":"2018","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"yoi250081r2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067606","article-title":"Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis.","volume":"378","author":"Stone","year":"2022","journal-title":"BMJ"},{"key":"yoi250081r3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3389\/fpsyt.2018.00517","article-title":"Statistically significant antidepressant-placebo differences on subjective symptom-rating scales do not prove that the drugs work: effect size and method bias matter!","volume":"9","author":"Hengartner","year":"2018","journal-title":"Front Psychiatry"},{"issue":"15","key":"yoi250081r4","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression.","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"yoi250081r5","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/s41591-021-01524-1","article-title":"Caution at psychiatry\u2019s psychedelic frontier.","volume":"27","author":"Burke","year":"2021","journal-title":"Nat Med"},{"issue":"9","key":"yoi250081r6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial.","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"issue":"12","key":"yoi250081r7","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"key":"yoi250081r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101809","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial.","volume":"56","author":"von Rotz","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"9","key":"yoi250081r9","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials.","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"yoi250081r10","doi-asserted-by":"publisher","first-page":"12107","DOI":"10.1038\/s41598-023-34938-7","article-title":"The difference between \u2018placebo group\u2019 and \u2018placebo control\u2019: a case study in psychedelic microdosing.","volume":"13","author":"Szigeti","year":"2023","journal-title":"Sci Rep"},{"issue":"12","key":"yoi250081r12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.49026","article-title":"Psilocybin therapy for clinicians with symptoms of depression from frontline care during the COVID-19 pandemic: a randomized clinical trial.","volume":"7","author":"Back","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"yoi250081r13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: A randomized, double-blind, placebo-controlled phase II study.","volume":"93","author":"Holze","year":"2023","journal-title":"Biol Psychiatry"},{"issue":"10","key":"yoi250081r14","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial.","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"yoi250081r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101505","article-title":"Assessment of blinding in randomized controlled trials of antidepressants for depressive disorders 2000-2020: a systematic review and meta-analysis.","volume":"50","author":"Lin","year":"2022","journal-title":"EClinicalMedicine"},{"key":"yoi250081r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.114297","article-title":"A systematic review and meta-analysis of the success of blinding in antidepressant RCTs.","volume":"307","author":"Scott","year":"2022","journal-title":"Psychiatry Res"},{"issue":"15","key":"yoi250081r18","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1056\/NEJMe2102835","article-title":"Back to the future\u2014the therapeutic potential of psychedelic drugs.","volume":"384","author":"Lieberman","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"yoi250081r20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/bmjebm-2020-111600","article-title":"Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression.","volume":"27","author":"Hengartner","year":"2022","journal-title":"BMJ Evid Based Med"},{"issue":"3","key":"yoi250081r21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4088\/JCP.10m06176blu","article-title":"Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA).","volume":"72","author":"Lamers","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"yoi250081r22","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796019000088","article-title":"Translating the BDI and BDI-II into the HAMD and vice versa with equipercentile linking.","volume":"29","author":"Furukawa","year":"2019","journal-title":"Epidemiol Psychiatr Sci"},{"key":"yoi250081r23","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jad.2017.09.042","article-title":"Translating the HAM-D into the MADRS and vice versa with equipercentile linking.","volume":"226","author":"Leucht","year":"2018","journal-title":"J Affect Disord"},{"issue":"5","key":"yoi250081r24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","article-title":"The 16-item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.","volume":"54","author":"Rush","year":"2003","journal-title":"Biol Psychiatry"},{"issue":"1","key":"yoi250081r26","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/00273171.2017.1365684","article-title":"On the multilevel nature of meta-analysis: a tutorial, comparison of software programs, and discussion of analytic choices.","volume":"53","author":"Pastor","year":"2018","journal-title":"Multivariate Behav Res"},{"issue":"1","key":"yoi250081r27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3758\/s13423-016-1221-4","article-title":"The bayesian new statistics: hypothesis testing, estimation, meta-analysis, and power analysis from a bayesian perspective.","volume":"25","author":"Kruschke","year":"2018","journal-title":"Psychon Bull Rev"},{"issue":"1","key":"yoi250081r28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.clinph.2015.05.032","article-title":"EEG alpha asymmetry as a gender-specific predictor of outcome to acute treatment with different antidepressant medications in the randomized iSPOT-D study.","volume":"127","author":"Arns","year":"2016","journal-title":"Clin Neurophysiol"},{"issue":"3","key":"yoi250081r29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/13651500310001446","article-title":"Quality of Life in 833 outpatients with major depression treated with open-label venlafaxine extended release: an observational 24-week study.","volume":"7","author":"Cervera-Enguix","year":"2003","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"12","key":"yoi250081r30","doi-asserted-by":"publisher","first-page":"E173","DOI":"10.1002\/da.20458","article-title":"Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.","volume":"25","author":"Chokka","year":"2008","journal-title":"Depress Anxiety"},{"issue":"6","key":"yoi250081r31","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/hup.2557","article-title":"Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world study.","volume":"31","author":"Gargoloff","year":"2016","journal-title":"Hum Psychopharmacol"},{"key":"yoi250081r32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-244X-7-43","article-title":"Duloxetine in the treatment of major depressive disorder: an open-label study.","volume":"7","author":"Hudson","year":"2007","journal-title":"BMC Psychiatry"},{"key":"yoi250081r33","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1076459","article-title":"Serotonergic psychedelics for depression: what do we know about neurobiological mechanisms of action?","volume":"13","author":"Husain","year":"2023","journal-title":"Front Psychiatry"},{"key":"yoi250081r34","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18m12202","article-title":"Symptomatic and functional outcomes and early prediction of response to escitalopram monotherapy and sequential adjunctive aripiprazole therapy in patients with major depressive disorder: a CAN-BIND-1 report.","author":"Kennedy","year":"2019","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"yoi250081r35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/da.20619","article-title":"Ethnic differences in antidepressant response: a prospective multi-site clinical trial.","volume":"27","author":"Lesser","year":"2010","journal-title":"Depress Anxiety"},{"issue":"7","key":"yoi250081r37","first-page":"364","article-title":"An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder.","volume":"105","author":"Pinto","year":"2007","journal-title":"J Indian Med Assoc"},{"issue":"7","key":"yoi250081r38","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3109\/15622975.2014.987814","article-title":"What to expect from a third step in treatment resistant depression: a prospective open study on escitalopram.","volume":"16","author":"Souery","year":"2015","journal-title":"World J Biol Psychiatry"},{"issue":"2","key":"yoi250081r39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3109\/10401239909147051","article-title":"An open-label trial of sertraline for the treatment of major depression in primary care.","volume":"11","author":"Taragano","year":"1999","journal-title":"Ann Clin Psychiatry"},{"issue":"10","key":"yoi250081r40","doi-asserted-by":"publisher","first-page":"782","DOI":"10.4088\/JCP.v62n1006","article-title":"Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients.","volume":"62","author":"Thase","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"yoi250081r41","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"8","key":"yoi250081r42","doi-asserted-by":"publisher","first-page":"802","DOI":"10.4088\/JCP.13m08360","article-title":"A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.","volume":"74","author":"Trivedi","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"yoi250081r43","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4088\/JCP.v58n0103","article-title":"Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline.","volume":"58","author":"Thase","year":"1997","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"yoi250081r44","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"yoi250081r45","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial.","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"18","key":"yoi250081r46","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression.","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"yoi250081r47","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial.","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychol Med"},{"issue":"7","key":"yoi250081r48","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1177\/02698811231154852","article-title":"Psilocybin-assisted therapy for major depressive disorder: an exploratory placebo-controlled, fixed-order trial.","volume":"37","author":"Sloshower","year":"2023","journal-title":"J Psychopharmacol"},{"issue":"12","key":"yoi250081r49","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial.","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"3","key":"yoi250081r50","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jpainsymman.2023.06.006","article-title":"HOPE: a pilot study of psilocybin enhanced group psychotherapy in patients with cancer.","volume":"66","author":"Lewis","year":"2023","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"yoi250081r51","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.medj.2024.01.005","article-title":"Psilocybin-assisted psychotherapy for treatment resistant depression: a randomized clinical trial evaluating repeated doses of psilocybin.","volume":"5","author":"Rosenblat","year":"2024","journal-title":"Med"},{"issue":"2","key":"yoi250081r52","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1177\/2515245918771304","article-title":"Rejecting or accepting parameter values in bayesian estimation.","volume":"1","author":"Kruschke","year":"2018","journal-title":"Adv Methods Pract Psychol Sci"},{"issue":"1","key":"yoi250081r53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/geronb\/gby065","article-title":"Improving inferences about null effects with Bayes factors and equivalence tests.","volume":"75","author":"Lakens","year":"2020","journal-title":"J Gerontol B Psychol Sci Soc Sci"},{"issue":"7","key":"yoi250081r54","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.24119","article-title":"Control group outcomes in trials of psilocybin, SSRIs, or esketamine for depression: a meta-analysis.","volume":"8","author":"Hieronymus","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"10","key":"yoi250081r56","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1007\/s00213-022-06221-6","article-title":"Expectancy in placebo-controlled trials of psychedelics: if so, so what?","volume":"239","author":"Butler","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"yoi250081r59","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2025.116359","article-title":"A systematic review of participant diversity in psychedelic-assisted psychotherapy trials.","volume":"345","author":"Haft","year":"2025","journal-title":"Psychiatry Res"},{"issue":"9","key":"yoi250081r60","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1176\/appi.ps.202100559","article-title":"Socioeconomic predictors of treatment outcomes among adults with major depressive disorder.","volume":"73","author":"Mills","year":"2022","journal-title":"Psychiatr Serv"},{"issue":"5","key":"yoi250081r61","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.bpsc.2024.02.004","article-title":"Expectancy effects in psychedelic trials.","volume":"9","author":"Szigeti","year":"2024","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"issue":"4","key":"yoi250081r62","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S2215-0366(23)00438-8","article-title":"Heterogeneity of outcome measures in depression trials and the relevance of the content of outcome measures to patients: a systematic review.","volume":"11","author":"Veal","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"yoi250081r63","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102799","article-title":"Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial.","volume":"76","author":"Erritzoe","year":"2024","journal-title":"EClinicalMedicine"},{"key":"yoi250081r25","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019","edition":"2nd ed"},{"key":"yoi250081r36","article-title":"Agomelatine as monotherapy for major depression: an outpatient, open-label study.","volume-title":"Neuropsychiatr Dis Treat","author":"Pecenak"},{"key":"yoi250081r55","first-page":"e078607","article-title":"Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and bayesian network meta-analysis.","volume-title":"BMJ","author":"Hsu","year":"2024"},{"key":"yoi250081r11","doi-asserted-by":"crossref","unstructured":"Van Elk? M, Fried? EI. History repeating: a roadmap to address common problems in psychedelic science.? PsyArXiv. Preprint posted on March 10, 2023. doi:10.31234\/osf.io\/ak6gx","DOI":"10.31234\/osf.io\/ak6gx"},{"key":"yoi250081r15","unstructured":"US Food and Drug Administration. Psychopharmacologic Drugs Advisory Committee (PDAC) meeting June 4, 2024. Accessed November 25, 2024. https:\/\/www.youtube.com\/watch?v=JqQKP8gcY1E"},{"key":"yoi250081r19","unstructured":"AsPredicted. Psychedelic therapy vs. open-label antidepressant treatment (AsPredicted #142,691). September 5, 2023. Accessed January 22, 2026. https:\/\/aspredicted.org\/35V_DWY"},{"key":"yoi250081r57","unstructured":"Cybin. Cybin announces unprecedented positive phase 2 interim data for CYB003 in major depressive disorder meeting primary efficacy endpoint with rapid and significant improvements in depression symptoms after single dose. October 31, 2023. Accessed January 24, 2025. https:\/\/www.businesswire.com\/news\/home\/20231031220551\/en\/Cybin-Announces-Unprecedented-Positive-Phase-2-Interim-Data-for-CYB003-in-Major-Depressive-Disorder-Meeting-Primary-Efficacy-Endpoint-with-Rapid-and-Significant-Improvements-in-Depression-Symptoms-After-Single-Dose"},{"key":"yoi250081r58","unstructured":"GH Research. GH Research announces primary endpoint met in phase 2b trial with GH001 in TRD demonstrating -15.5 point placebo-adjusted MADRS reduction. February 3, 2025. Accessed March 28, 2025. https:\/\/www.globenewswire.com\/news-release\/2025\/02\/03\/3019385\/0\/en\/GH-Research-Announces-Primary-Endpoint-Met-in-Phase-2b-Trial-with-GH001-in-TRD-Demonstrating-15-5-Point-Placebo-adjusted-MADRS-Reduction.html"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2846479\/jamapsychiatry_williams_2026_oi_250081_1777052925.93618.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:00:42Z","timestamp":1778079642000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2846479"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.4809","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}